INO stock is gaining momentum in the pre-marker session on Wednesday after Inovio Pharmaceuticals Inc (NASDAQ:INO) Pan-COVID-19 vaccine candidate (INO-4802) induces broad immunity against major viral variants in preclinical studies.
Co announced that its next-generation Pan-COVID-19 vaccine candidate, INO-4802, induced potent neutralizing antibodies and T cell responses against the original Wuhan strain as well as against B.1.1.7 (UK variant), B.1.351 (South African variant) and P.1. (Brazilian variant) in preclinical models.
These results demonstrate the potential of INOVIO’s Pan-COVID-19 vaccine to induce cross-reactive immune responses against current and emerging viral variants as either a first-line vaccine, or potentially as a boost for individuals previously immunized with various Wuhan-matched vaccines.
INO stock is up 6.32% at $6.90. The stock was down 2.70% in the regular session on Tuesday. The stock has lost almost 60% from its February’s peak price.
Editor and Computer Expert
A hardcore tech enthusiast and computer expert Uson Abdilazhanov who holds a degree in communications started writing in his personal blogs since 2012. That time he was interested in the technical part of the computer. But now the software aspect plays an important role in his career. Currently, he runs a PC building and repairing shop which helps a lot of designers and gamers who always like to try new things.